Cargando…

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer

BACKGROUND: Cognitive effects of tamoxifen have been described. We augment data from a previous short-term (ST) follow-up study with long-term (LT) data to evaluate ST and LT cognitive effects of tamoxifen followed by exemestane and exemestane in breast cancer patients. METHODS: Patients from the Ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee Meeuw Kjoe, Philippe R, Kieffer, Jacobien M, Small, Brent J, Boogerd, Willem, Schilder, Christina M, van der Wall, Elsken, Meershoek-Klein Kranenbarg, Elma, van de Velde, Cornelis J H, Schagen, Sanne B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121337/ https://www.ncbi.nlm.nih.gov/pubmed/37004168 http://dx.doi.org/10.1093/jncics/pkad022

Ejemplares similares

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
por: Bertelli, G., et al.
Publicado: (2010)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
por: Aktas, Bilge, et al.
Publicado: (2016)

Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
por: Thomas, R, et al.
Publicado: (2008)

Trajectories of Cognitive Symptoms in Sick-Listed Cancer Survivors
por: Klaver, Kete M., et al.
Publicado: (2021)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type
por: Menning, Sanne, et al.
Publicado: (2017)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment — The role of fatigue
por: Menning, Sanne, et al.
Publicado: (2015)

The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival
por: Houtsma, Danny, et al.
Publicado: (2021)

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
por: Barnadas, A, et al.
Publicado: (2009)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
por: Smit, Marloes, et al.
Publicado: (2019)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2013)

Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial
por: Guerrieri-Gonzaga, Aliana, et al.
Publicado: (2021)

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2014)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Exemestane in early breast cancer: a review
por: Untch, Michael, et al.
Publicado: (2008)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial
por: Slagter, Astrid E., et al.
Publicado: (2020)

Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial
por: Caspers, Irene A., et al.
Publicado: (2021)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

A review of the use of exemestane in early breast cancer
por: Robinson, Andrew
Publicado: (2009)

Exemestane/palbociclib/prednisolone: Various toxicities: case report
Publicado: (2020)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study
por: Nagtegaal, Iris D, et al.
Publicado: (2001)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user
por: Jaegle, William T., et al.
Publicado: (2017)

Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer
por: Slagter, Astrid E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q6eju0iju4flfe5shsdh6tps28